Grossman - Figure 14
ABC Meta-analysis Collaboration: Overall Survival Hazard Ratio Plot
FIG. 14: This Figure shows the results of one of several meta-analyses of cisplatin-based chemotherapy prior to definitive treatment, all of which showed similar results. This meta-analysis[5] explored cisplatin alone versus cisplatin-based combinations and found that patients who received single-agent cisplatin did not show an improvement in overall survival. Patients receiving cisplatin-based combinations, however, did show a statistically significant improvement in overall survival, with a hazard ratio (HR) of 0.86 (P=0.003).
References
Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol. 2005;48:202−5 http://dx.doi.org/10.1016/j.eururo.2005.04.006